Macromycin Tablet contains Spiramycin 3 Million IU, a macrolide antibiotic effective against a broad spectrum of gram-positive and certain gram-negative bacteria. It is primarily indicated for the treatment of respiratory tract infections, skin and soft tissue infections, and toxoplasmosis, particularly in pregnant women to reduce fetal transmission. Spiramycin exerts its antibacterial action by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, thereby preventing bacterial growth and replication. Macromycin is well-absorbed orally and achieves therapeutic concentrations in various tissues, including the lungs and placenta. It is generally well-tolerated, with common adverse effects including gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Caution is advised in patients with hepatic impairment and those with known hypersensitivity to macrolides. Macromycin should be administered as prescribed, completing the full course of therapy to prevent resistance development. It is contraindicated in patients with a history of macrolide allergy and should be used with caution when co-administered with drugs metabolized by the cytochrome P450 system due to potential drug interactions. Macromycin Tablet offers an effective therapeutic option for managing bacterial infections where macrolide therapy is indicated.